Display options
Cite
Price D, Burris D, Cloutier A, et al. Dose-Dependent and Lasting Influences of Intranasal Vasopressin on Face Processing in Men. Front Endocrinol (Lausanne). 2017;8:220doi: 10.3389/fendo.2017.00220.
Price, D., Burris, D., Cloutier, A., Thompson, C. B., Rilling, J. K., & Thompson, R. R. (2017). Dose-Dependent and Lasting Influences of Intranasal Vasopressin on Face Processing in Men. Frontiers in endocrinology, 8220. https://doi.org/10.3389/fendo.2017.00220
Price, Daniel, et al. "Dose-Dependent and Lasting Influences of Intranasal Vasopressin on Face Processing in Men." Frontiers in endocrinology vol. 8 (2017): 220. doi: https://doi.org/10.3389/fendo.2017.00220
Price D, Burris D, Cloutier A, Thompson CB, Rilling JK, Thompson RR. Dose-Dependent and Lasting Influences of Intranasal Vasopressin on Face Processing in Men. Front Endocrinol (Lausanne). 2017 Sep 22;8:220. doi: 10.3389/fendo.2017.00220. eCollection 2017. PMID: 29018407; PMCID: PMC5614924.
Copy Download .nbib Format: NLM
Share it on

Front Endocrinol (Lausanne). 2017 Sep 22;8:220. doi: 10.3389/fendo.2017.00220. eCollection 2017.

Dose-Dependent and Lasting Influences of Intranasal Vasopressin on Face Processing in Men.

Frontiers in endocrinology

Daniel Price, Debra Burris, Anna Cloutier, Carol B Thompson, James K Rilling, Richmond R Thompson

Affiliations

  1. Maine Medical Center, Department of Psychiatry, Portland, ME, United States.
  2. Biostatistics Center, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States.
  3. Department of Anthropology, Emory University, Atlanta, GA, United States.
  4. Department of Psychiatry and Behavioral Science, Emory University, Atlanta, GA, United States.
  5. Center for Translational Social Neuroscience, Emory University, Atlanta, GA, United States.
  6. The Center for Social Neuroscience, Atlanta, GA, United States.
  7. Psychology Department and Neuroscience Program, Bowdoin College, Brunswick, ME, United States.

PMID: 29018407 PMCID: PMC5614924 DOI: 10.3389/fendo.2017.00220

Abstract

Arginine vasopressin (AVP) and related peptides have diverse effects on social behaviors in vertebrates, sometimes promoting affiliative interactions and sometimes aggressive or antisocial responses. The type of influence, in at least some species, depends on social contexts, including the sex of the individuals in the interaction and/or on the levels of peptide within brain circuits that control the behaviors. To determine if AVP promotes different responses to same- and other-sex faces in men, and if those effects are dose dependent, we measured the effects of two doses of AVP on subjective ratings of male and female faces. We also tested if any influences persist beyond the time of drug delivery. When AVP was administered intranasally on an initial test day, 20 IU was associated with decreased social assessments relative to placebo and 40 IU, and some of the effects persisted beyond the initial drug delivery and appeared to generalize to novel faces on subsequent test days. In single men, those influences were most pronounced, but not exclusive, for male faces, whereas in coupled men they were primarily associated with responses to female faces. Similar influences were not observed if AVP was delivered after placebo on a second test day. In a preliminary analysis, the differences in social assessments observed between men who received 20 and 40 IU, which we suggest primarily reflect lowered social assessments induced by the lower dose, appeared most pronounced in subjects who carry what has been identified as a risk allele for the V1a receptor gene. Together, these results suggest that AVP's effects on face processing, and possibly other social responses, differ according to dose, depend on relationship status, and may be more prolonged than previously recognized.

Keywords: V1a receptor; face processing; intranasal; social behavior; social context

References

  1. Hum Brain Mapp. 2016 Jul;37(7):2700-9 - PubMed
  2. Neuroreport. 1994 Jun 2;5(10):1181-4 - PubMed
  3. Proc Biol Sci. 2006 Dec 22;273(1605):3085-92 - PubMed
  4. Horm Behav. 2016 May;81:20-7 - PubMed
  5. Peptides. 1989 Jul-Aug;10(4):717-20 - PubMed
  6. Biol Psychiatry. 2010 Jun 15;67(12):1220-2 - PubMed
  7. Neuropsychopharmacology. 2013 Oct;38(11):2249-59 - PubMed
  8. Psychoneuroendocrinology. 2012 Apr;37(4):576-80 - PubMed
  9. Front Behav Neurosci. 2016 Mar 29;10:58 - PubMed
  10. Mol Biol Evol. 2010 Jun;27(6):1269-78 - PubMed
  11. Arch Gen Psychiatry. 1998 Aug;55(8):708-14 - PubMed
  12. Neuroscience. 2004;125(1):35-45 - PubMed
  13. Psychoneuroendocrinology. 2012 Apr;37(4):447-61 - PubMed
  14. Behav Neurosci. 2001 Aug;115(4):910-9 - PubMed
  15. Horm Behav. 2016 Feb;78:20-31 - PubMed
  16. Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14153-6 - PubMed
  17. Horm Behav. 2009 Jun;56(1):101-7 - PubMed
  18. Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2051-6 - PubMed
  19. Genes Brain Behav. 2008 Apr;7(3):266-75 - PubMed
  20. Psychoneuroendocrinology. 2015 Jan;51:253-61 - PubMed
  21. Nat Neurosci. 2013 Jul;16(7):919-24 - PubMed
  22. Front Neuroendocrinol. 2015 Jan;36:49-71 - PubMed
  23. Neurosci Lett. 2016 Nov 10;634:107-113 - PubMed
  24. Biol Lett. 2009 Aug 23;5(4):554-6 - PubMed
  25. Psychoneuroendocrinology. 2014 Jan;39:237-48 - PubMed
  26. Front Neurosci. 2014 Jun 24;8:171 - PubMed
  27. Psychiatry Res. 2015 Feb 28;225(3):739-40 - PubMed
  28. Physiol Behav. 2011 Mar 1;102(3-4):296-303 - PubMed
  29. Horm Behav. 2012 Mar;61(3):392-9 - PubMed
  30. Brain Res Brain Res Rev. 2001 Jul;35(3):246-65 - PubMed
  31. Front Endocrinol (Lausanne). 2017 Aug 21;8:200 - PubMed
  32. Eur Neuropsychopharmacol. 1991 May;1(2):123-6 - PubMed
  33. Genes Brain Behav. 2012 Jul;11(5):552-8 - PubMed
  34. J Neurosci. 2012 Nov 14;32(46):16074-9 - PubMed
  35. J Neuroendocrinol. 2000 Apr;12(4):361-7 - PubMed
  36. Proc Natl Acad Sci U S A. 2009 Nov 10;106(45):19144-9 - PubMed
  37. Proc Natl Acad Sci U S A. 2006 May 16;103(20):7889-94 - PubMed
  38. Horm Behav. 2011 Jun;60(1):121-7 - PubMed
  39. PLoS One. 2015 Aug 21;10(8):e0136436 - PubMed
  40. Mol Psychiatry. 2002;7(5):503-7 - PubMed
  41. J Comp Neurol. 2007 Jun 20;502(6):1109-22 - PubMed
  42. Brain Res. 1988 Aug 2;457(1):143-7 - PubMed
  43. PLoS One. 2012;7(12):e49708 - PubMed
  44. Horm Behav. 2004 Feb;45(2):136-43 - PubMed
  45. Horm Behav. 2016 May;81:68-73 - PubMed
  46. Front Endocrinol (Lausanne). 2015 May 19;6:76 - PubMed
  47. Ann N Y Acad Sci. 1999 Jun 29;877:242-57 - PubMed
  48. Nat Neurosci. 2002 Jun;5(6):514-6 - PubMed
  49. Psychoneuroendocrinology. 2011 Feb;36(2):294-7 - PubMed
  50. Psychoneuroendocrinology. 2014 Dec;50:14-9 - PubMed
  51. Nat Neurosci. 2006 Jan;9(1):133-9 - PubMed
  52. Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):6069-74 - PubMed
  53. Psychoneuroendocrinology. 2013 Nov;38(11):2554-61 - PubMed
  54. Psychopharmacology (Berl). 2012 Mar;220(2):319-30 - PubMed
  55. Nature. 2000 Feb 17;403(6771):769-72 - PubMed
  56. Behav Neurosci. 1999 Oct;113(5):1071-9 - PubMed
  57. Psychoneuroendocrinology. 2009 Jul;34(6):901-8 - PubMed
  58. Front Psychiatry. 2015 Sep 22;6:130 - PubMed
  59. Eur J Neurosci. 2010 May;31(9):1655-63 - PubMed
  60. Genes Brain Behav. 2011 Apr;10(3):375-83 - PubMed
  61. Front Neuroendocrinol. 2009 Oct;30(4):429-41 - PubMed
  62. Nature. 1993 Oct 7;365(6446):545-8 - PubMed
  63. Psychoneuroendocrinology. 2013 Apr;38(4):465-78 - PubMed
  64. Science. 2012 Jun 1;336(6085):1154-7 - PubMed
  65. Psychopharmacology (Berl). 1987;91(3):363-8 - PubMed
  66. Psychoneuroendocrinology. 2004 Jan;29(1):35-48 - PubMed
  67. Mol Psychiatry. 2009 Oct;14(10):968-75 - PubMed
  68. Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13233-13238 - PubMed

Publication Types

Grant support